Literature DB >> 10977393

Expert judgement in pharmacoeconomic studies. Guidance and future use.

C Evans1, B Crawford.   

Abstract

Research in the field of pharmacoeconomics has increased substantially during the past decade. Much of this research has been on the design and analysis of data concerning the relative merits of one drug or device compared with another in terms of costs and effects. Concomitant with these evaluations has been the development of guidelines for the conduct of economic evaluations in several countries. However, despite an increase in research, little attention has been paid to how different study designs may influence the results of a study. The use of expert judgement in decision analytic modelling is one area where design issues may influence the findings of a study. This issue is examined for the case of modified Delphi and Delphi panels. Although the use of expert opinion in modelling studies seems to be widespread, there is little consistent application, understanding or reporting of the techniques used. In particular, the definitions of techniques vary between studies, the criteria for determining when consensus is reached vary, and the reporting of these criteria is absent. Future studies using expert judgement should be more aware of the controversies surrounding the issue and provide more reporting of the techniques used. It is proposed that future validation exercises may assist researchers in determining the most appropriate application of methods.

Mesh:

Year:  2000        PMID: 10977393     DOI: 10.2165/00019053-200017060-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  10 in total

1.  The cost-effectiveness of a new chlorhexidine delivery system in the treatment of adult periodontitis.

Authors:  G De Lissovoy; A M Rentz; E M Dukes; C A Eaton; M K Jeffcoat; W J Killoy; R D Finkelman
Journal:  J Am Dent Assoc       Date:  1999-06       Impact factor: 3.634

2.  Cost-effectiveness analysis of periodontal disease control.

Authors:  A A Antczak-Bouckoms; M C Weinstein
Journal:  J Dent Res       Date:  1987-11       Impact factor: 6.116

3.  Reporting format for economic evaluation. Part I: Application to the Dutch healthcare system.

Authors:  M J Nuijten; M J Brorens; Y A Hekster; A van der Kuy; J H Lockefeer; P A de Smet; G Bonsel; M H Pronk
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981

4.  Reporting format for economic evaluation. Part II: Focus on modelling studies.

Authors:  M J Nuijten; M H Pronk; M J Brorens; Y A Hekster; J H Lockefeer; P A de Smet; G Bonsel; A van der Kuy
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

Review 5.  The use of consensus methods and expert panels in pharmacoeconomic studies. Practical applications and methodological shortcomings.

Authors:  C Evans
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

6.  Health and economic outcomes modeling practices: a suggested framework.

Authors:  M T Halpern; B R Luce; R E Brown; B Geneste
Journal:  Value Health       Date:  1998 Jul-Aug       Impact factor: 5.725

7.  Judgment under Uncertainty: Heuristics and Biases.

Authors:  A Tversky; D Kahneman
Journal:  Science       Date:  1974-09-27       Impact factor: 47.728

Review 8.  Consensus methods for medical and health services research.

Authors:  J Jones; D Hunter
Journal:  BMJ       Date:  1995-08-05

9.  Use of economic evaluation guidelines: 2 years' experience in Canada.

Authors:  J F Baladi; D Menon; N Otten
Journal:  Health Econ       Date:  1998-05       Impact factor: 3.046

10.  Cost analysis of palliative care for terminally ill cancer patients in the UK after switching from weak to strong opioids. Palliative Care Advisory Committee.

Authors:  J F Guest; W M Hart; R F Cookson
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

  10 in total
  10 in total

1.  Validation of expert opinion in identifying comorbidities associated with atopic dermatitis/eczema.

Authors:  Charles N Ellis; Lynn A Drake; Mary M Prendergast; William Abramovits; Mark Boguniewicz; C Ralph Daniel; Mark Lebwohl; Seth R Stevens; Diane L Whitaker-Worth; Kuo B Tong
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 2.  Tools for Assessing Potential Significance of Pharmacist Interventions: A Systematic Review.

Authors:  Thi-Ha Vo; Bruno Charpiat; Claire Catoire; Michel Juste; Renaud Roubille; François-Xavier Rose; Sébastien Chanoine; Jean-Luc Bosson; Ornella Conort; Benoît Allenet; Pierrick Bedouch
Journal:  Drug Saf       Date:  2016-02       Impact factor: 5.606

Review 3.  Methods to elicit probability distributions from experts: a systematic review of reported practice in health technology assessment.

Authors:  Bogdan Grigore; Jaime Peters; Christopher Hyde; Ken Stein
Journal:  Pharmacoeconomics       Date:  2013-11       Impact factor: 4.981

4.  Economic evaluation of intravenous itraconazole for presumed systemic fungal infections in neutropenic patients in Korea.

Authors:  K Moeremans; L Annemans; Ji-So Ryu; Kang-Won Choe; Wan-Shik Shine
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

5.  The appropriate elicitation of expert opinion in economic models: making expert data fit for purpose.

Authors:  William Sullivan; Katherine Payne
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

6.  Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations.

Authors:  Cynthia P Iglesias; Alexander Thompson; Wolf H Rogowski; Katherine Payne
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

7.  Structuring and validating a cost-effectiveness model of primary asthma prevention amongst children.

Authors:  G Feljandro P Ramos; Sandra Kuiper; Edward Dompeling; Antoinette D I van Asselt; Wim J C de Grauw; J André Knottnerus; Onno C P van Schayck; Tjard R J Schermer; Johan L Severens
Journal:  BMC Med Res Methodol       Date:  2011-11-09       Impact factor: 4.615

8.  Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?

Authors:  Saskia Schawo; Annemarie van der Kolk; Clazien Bouwmans; Lieven Annemans; Maarten Postma; Jan Buitelaar; Michel van Agthoven; Leona Hakkaart-van Roijen
Journal:  Pharmacoeconomics       Date:  2015-05       Impact factor: 4.981

9.  Association between societal costs and treatment response in children and adolescents with ADHD and their parents. A cross-sectional study in the Netherlands.

Authors:  Annemarie van der Kolk; Clazien Am Bouwmans; Saskia J Schawo; Jan K Buitelaar; Michel van Agthoven; Leona Hakkaart-van Roijen
Journal:  Springerplus       Date:  2015-05-15

10.  Early decision-analytic modeling - a case study on vascular closure devices.

Authors:  Alina Brandes; Moritz F Sinner; Stefan Kääb; Wolf H Rogowski
Journal:  BMC Health Serv Res       Date:  2015-10-27       Impact factor: 2.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.